Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway by Zuo, Lian et al.
Zuo et al. Breast Cancer Research 2010, 12:R34
http://breast-cancer-research.com/content/12/3/R34
Open Access RESEARCH ARTICLE
© 2010 Zuo et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons At-
tribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Research article Progesterone reverses the mesenchymal 
phenotypes of basal phenotype breast cancer cells 
via a membrane progesterone receptor mediated 
pathway
Lian Zuo, Wei Li and Shaojin You*
Abstract
Introduction: Basal phenotype breast cancers (BPBC) are often associated with apparent epithelial to mesenchymal 
transition (EMT). The role of progesterone (P4) in regulating EMT of BPBC has not been reported.
Methods: The EMT relevant biology was investigated in vitro using human BPBC cell models (MDA-MB468 and MDA-
MB231) with P4, PR agonist (RU486), and PR antagonist (R5020) treatments. The essential role of membrane 
progesterone receptor α (mPRα) in the P4-regulated EMT was demonstrated by knocking down the endogenous gene 
and/or stably transfecting exogenous mPRα gene in the BPBC cell models.
Results: The expression of snail and down-stream EMT proteins such as occludin, fibronectin, and E-cadherin was 
significantly regulated by P4 incubation, which was accompanied by cell morphological reversion from mesenchymal 
to epithelial phenotypes. In searching for the cell mediator of P4' action in the MDA-MB468 (MB468) cells, it was found 
that mPRα but not the nuclear PR has an essential role in the P4 mediated EMT inhibition. Knocking down the 
expression of mPRα with specific siRNA blocked the P4's effects on expression of the EMT proteins. In another BPBC cell 
line - MDA-MB231 (MB231), which is mPRα negative by Western blotting, P4 treatment did not alter cell proliferation 
and EMT protein expressions. Introduction of the exogenous mPRα cDNA into these cells caused cell proliferation, but 
not EMT, to become responsive to P4 treatment. In further studies, it was found that activation of the PI3K/Akt pathway 
is necessary for the P4-induced EMT reversion. To define the potential inter-mediate steps between mPRα and PI3K, we 
demonstrated that mPRα, caveolin-1 (Cav-1), and epidermal growth factor receptor (EGFR) are colocalized in the 
membrane of caveolar vesicle and the P4-repressed EMT in MB468 cells can be blocked by EGFR inhibitor (AG1478) and 
PI3K inhibitor (wortmannin).
Conclusions: Our data suggest that the signaling cascade of P4 induced mesenchymal repression is mediated 
through mPRα and other caveolae bound signaling molecules namely Cav-1, EGFR, and PI3K. This novel finding may 
have great impact on fully understanding the pathogenesis of BPBC and provide an essential clue for developing a 
targeted therapeutic strategy for treatment of BPBC.
Introduction
Basal phenotype breast cancer (BPBC) is a subtype of
cancer with apparent mesenchymal phenotypes. Boyer
and colleagues first described a morphologic change
from epithelial-like sheets of cultured cancer cells to scat-
tered, fibroblast-like cells capable of invading the base-
ment membrane, so called epithelial to mesenchymal
transition (EMT) [1]. The morphologic criteria of EMT
in vitro involve changes in cell polarity, separation into
individual cells and acquisition of cell motility [2]. These
changes can be either stable or reversible. The essential
changes in gene expression that disrupt cell polarity and
cause mesenchymal transition have been identified. Snail,
twist, and slug have been shown as key regulators of EMT
in both animal and human cancers [3]. Among these
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genes, snail acts as a transcriptional factor to repress
genes that encode the cell-cell junctional apparatus, such
as E-cadherin and occludin; and to enhance genes that
encode mesenchymal or tumor interstitial components,
such as fibronectin and vimentin, resulting in a dediffer-
entiated mesenchymal transition characterized by
increased cell motility [4,5].
The roles of female sex hormones such as progesterone
(P4) in the pathogenesis of BPBC remain unclear. Classi-
cally, the actions of P4 on cancer cells are attributed to
the binding of nuclear progesterone receptor (PR), trans-
location of P4/PR complex into the nucleus and subse-
quent activation of target genes over the course of several
hours. These mechanisms, however, are not applicable to
BPBC due to a lack or very low level of PR expression in
these cancers. The mechanisms for P4's actions in modu-
l a t i n g  t h e  c a n c e r  b i o l o g y  o f  B P B C  r e m a i n  l a r g e l y
unknown. Recently, the cell membrane hormonal recep-
tors, such as membrane progesterone receptor (mPR)
family and progestin membrane receptor component 1
(PGMRC1), were identified and demonstrated functional
in BPBC [6,7]. It is believed that the rapid responses of P4
are initiated at the cell surface by binding to the mem-
brane receptors [8-10]. For examples, progestin, a syn-
thetic P4, has been shown to activate a variety of signaling
pathways through mPRα [6]. The binding of progestin to
mPRα alters the secondary messenger pathways through
activation of the pertussis toxin-sensitive inhibitory G-
proteins and then activates the mitogen activated protein
kinases (MAPK)/Erk 1/2 pathway [6,7,11,12]. However,
this theory has been debated because others failed to
demonstrate mPRs on the cell surface or mediate P4-
dependent signaling events, such as coupling to G pro-
teins [13]. Moreover, mPRs were shown to be primarily
situated in the endoplasmic reticulum [13,14]. In this
study, we co-localized mPRα, caveolin-1 (Cav-1), and epi-
dermal growth factor receptor (EGFR) at a specified
membrane structure, so called caveolar vesicle, and dem-
onstrated that P4 reverses the mesenchymal phenotypes
of human BPBC cells (MB468 and MB231) via a caveolae
bound signaling complex namely mPRα, Cav-1, EGFR,
and PI3K/Akt. Further study on this unique molecular
pathway may afford great potential to discover novel
molecular targets for treatment of BPBC.
Materials and methods
Chemicals and antibodies
RU486 (mifepristone), AG1498, wortmannin, PP1 and
PD98052 were purchased from EMD Chemicals (Gibb-
stown, NJ, USA); R5020 (promegestone) and bpV (phen)
were from PerkinElmer (Waltham, MA, USA) and
Thermo Fisher Scientific (Pittsburgh, PA, USA), respec-
tively. Anti-snail antibody was from Abcam (1:1000,
Cambridge, MA, USA); anti-E-cadherin and anti-
fibronectin antibodies were obtained from EPITMICS
(1:1000, Burlingame, CA, USA); anti-mPRα, anti-
GAPDH (1:500) and secondary antibodies (1:2000) were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); anti-occludin antibody was from BD trans-
duction (1:500, San Jose, CA, USA); and anti-α-tubulin
antibody was from Sigma (1:2000, St. Louis, MO, USA).
Cell culture
The human breast cancer cell lines MDA-MB468
(MB468), MDA-MB231 (MB231) and human embryonic
kidney 293 (HEK 293) cells were obtained from the
American Type Culture Collection (Rockville, MD, USA).
Both human breast cancer cell lines were negative for
estrogen receptor (ER) and human epidermal growth fac-
tor receptor (Her)-2 and classified as 'basal phenotype A'
cells [15]. The cultured MB468 cells at early passages typ-
ically appear like epithelial cells with oval and/or polygo-
nal shapes [16]; and after multiple passages (50+), these
cells exhibit apparent mesenchymal phenotypes with
spindle and elongated shapes [see Additional file 1],
which are ideal for the proposed studies. Long-term cell
culture in vitro may generate genetic instabilities and the
derived cell lines with altered cell biological features have
been utilized as cell models for in vitro studies [17,18].
The late passage MB468 cells and early passage MB231
cells with apparent mesenchymal phenotypes [16] were
cultured and maintained at 37°C with 21% oxygen and 5%
carbon dioxide (without 5% carbon dioxide for MB231
and HEK293 culture) in DMEM (Sigma, St. Louis, MO,
USA) containing 10% FBS (Gibco, Carlsbad, CA, USA), 2
mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin (Gibco, Carlsbad, CA, USA) and main-
tained in a humidified incubator. The XTT cell prolifera-
tion assay kit was from Cayman Chemicals (Ann Arbor,
MI, USA).
Immunoblotting
Western blot assays were performed as described previ-
ously [19]. After treatment with or without P4 and/or
diverse pathway inhibitors, the growth-arrested cells
were lysed with 500 μl ice-cold lysis buffer, pH 7.4 (50
mM HEPES, 5 mM EDTA, 50 mM NaCl), 1% Triton X-
100, protease inhibitors (10 μg/ml aprotinin, 1 mM phe-
nylmethylsulfonyl fluoride, 10 μg/ml leupeptin) and
phosphatase inhibitors (50 mM sodium fluoride, 1 mM
sodium orthovanadate, 10 mM sodium pyrophosphate).
Cell lysates (25 μg) were separated using SDS-PAGE and
transferred to nitrocellulose membranes, blocked over-
night in PBS containing 6% nonfat dry milk and 0.1%
Tween 20, and incubated for one hour with primary anti-
bodies at proper dilutions. After incubation with second-
ary antibodies, proteins were detected by ECLZuo et al. Breast Cancer Research 2010, 12:R34
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chemiluminescence. Image J was used for quantitative
analysis.
Cell morphological changes of MB468 treated with P4
MB468 cells (105 cells/dish) were seeded and grown in 35
mm cell culture dishes (Bioptechs Inc., Butler, PA, USA)
for 24 hours. The medium was changed to complete cul-
ture medium with or without 30 ng/ml of P4 for 48 hours
and then cultured as indicated. Nomarski differential
interference contrast (DIC) images were taken using a
confocal microscopy (Olympus FV1000, Tokyo, Japan)
with a transmitted light at 400× magnification.
Cell proliferation assay
The XTT cell proliferation assay was performed accord-
ing to the manufacturer's protocol. Briefly, cells were
seeded in a 96-well plate in 100 μl of culture medium with
or without the compounds to be tested and incubated for
24 to 48 hours at 37°C. The reconstituted XTT mixture
(10 μl/well) was added and the cells were incubated for
two hours. The absorbance of each sample was subse-
quently measured using a microplate reader at a wave-
length of 450 nm.
Knocking down mPRα expression with small interference 
RNA
Cells were transfected with mPRα small interference
RNA (siRNA) or an equal amount of nonspecific control
siRNA (Dharmacon, Lafayette, CO, USA) using the Olig-
ofectamine reagents according to the manufacturer's pro-
tocol (Invitrogen, Carlsbad, CA, USA). Two days after
transfection with siRNA, the cells were incubated with
diverse experimental reagents.
Transfection of mPRα DNA plasmid
The MB231 cells were cultured and split when the cell
confluence reached about 90%. The human mPRα cDNA
constructed in a pUC-based plasmid with CMV pro-
moter (pBK-CMV) vector [20] was purified and then
transfected into the cells using Lipofectamine 2000
reagent following the manufacturer's instructions (Invit-
rogen, Carlsbad, CA, USA). Two days after transfection,
the mPRα expressing cells were selected with 1000 μg/ml
G418 (Gibco, Carlsbad, CA, USA). The resistant colonies
were then isolated and propagated with 500 μg/ml G418
in order to produce the stably transfected cell lines.
Isolation of caveolar fractions
Caveolae membranes were isolated as described previ-
ously [21]. Briefly, MB468 cells was homogenized in 1 ml
of 2-(N-morpholino) ethanesulfonic acid (MES)-buffered
saline (24 mM MES, pH 6.5, and 0.15 NaCl) plus 1% Tri-
ton X-100 and spun down at 3,000 g for five minutes at
4°C. The supernatant (4 ml) was used to dissolve sucrose
and compose 40% of sucrose solution. This solution was
placed in a 12.5-ml Beckman centrifuge tube (Beckman
Coulter, Fullerton, CA, USA) with a 5 to 30% sucrose gra-
dient layered on top and then centrafuged at 39,000 rpm
for 24 hours at 4°C in a Beckman SW-41 rotor. After the
centrafuge, 600 μl fractions of the solution were collected
and subjected to further analysis.
Immunohistochemical analysis
In brief, two tissue microarray slides consisting of human
breast cancer (140 and 70) cores and adjacent benign
breast tissue (10 and 24) cores were purchased from the
Biomax US (Rockville, MD, USA). These tissue microar-
ray slides were constructed with complete different sets
of tissue blocks. There were total 105 breast cancer and
17 benign breast tissues in these two tissue arrays. Two
1.5 mm-cores from each breast tissue block were con-
structed in the tissue microarray slides. After deparaffini-
zation, rehydration, antigen retrieval, and endogenous
peroxidase blocking, the slides were blocked with 5% nor-
mal horse serum for one hour and sequentially incubated
with anti-mPRα antibody (1:200 dilution) at 4°C over-
night and then incubated with a secondary antibody at
room temperature (see manual of the ImmPRESS
REAGENT kit, VECTOR Lab, CA). The color was devel-
oped with the ImmPACT DAB kit (VECTOR Lab, Burl-
ingame, CA, USA). Between the incubations, the slides
were washed twice with 1× PBS buffer (5 minutes each)
[19,22]. Two negative controls were included: (1) control
slides were stained without the primary antibody; (2)
control slides were incubated with a specific blocking
peptide (cat# sc-50111p, Santa Cruz, CA, USA) prior to
the primary antibody incubations. The immunostained
slides were counterstained with hematoxylin and evalu-
ated using a Nikon microscope with an Olympus digital
camera (Tokyo, Japan). The immunohistochemical result
was evaluated using a semi-quantitative scoring system
by a trained research pathologist, who was blinded to
patients' clinical data provided by the company. The
intensity of the immunostaining was defined into four
categories (strong positive, moderate, weak, and nega-
tive) [see Additional file 2].
Statistical analysis
The quantitative data was expressed as mean ± standard
error and statistical significance was assessed by Stu-
dent's paired two-tailed t-test. The positive rates of mPRα
immunostains in different groups of human breast can-
cers and benign diseases was compared and analyzed by
Fisher's exact test. P < 0.05 was considered significant.
Results
P4 regulates expression of snail and other EMT-relevant 
proteins in MB468 but not in MB231 cells
In this study, we focused on the effects of P4 on expres-
sion of snail and other EMT marker proteins. As shownZuo et al. Breast Cancer Research 2010, 12:R34
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in the Figures 1a and 1b, the snail expression in the late
passage MB468 cells was down-regulated by P4 treat-
ment in a dose-dependent (P4 at 15 ng/ml - 47.0 ± 7.4%;
30 ng/ml - 68.3 ± 6.7%; 60 ng/ml - 86.3 ± 1.6%; Figure 1a)
and time-dependent manners (6 hours - 20.0 ± 2.4%; 12
hours - 24.0 ± 3%; 24 hours - 87.0 ± 7.4%; 48 hrs - 94 ±
8.6%; Figure 1b). As snail has been known as a key modu-
lator for EMT [4,5], the P4-induced EMT relevant
changes were further investigated. As shown in Figure 1c,
fibronectin expression was significantly inhibited around
74.0 ± 3.7% by P4 treatment at 30 ng/ml while expression
of E-cadherin and occludin was up-regulated about 3.8
fold and 3.5 fold, respectively. Furthermore, the changes
in expression of snail/other EMT-relevant proteins were
followed by cell morphological changes. The late passage
MB468 cells without P4 exposure showed apparent mes-
enchymal phenotypes, characterized by diverse sizes and
spindle or elongated shapes are usually shown; while with
P4 treatment, most of the cells appeared epithelial-like
transition, featured by large and polygonal shapes or
small oval shapes (Figure 1d at 40×) [see Additional file
3]. In addition, the cell proliferation of MB468 was also
Figure 1 Dose curve and time course of P4's action on epithelial-mesenchymal transition relevant events of MB468 and MB231 cells. The 
growth-arrested MB468 cells were treated with different doses of progesterone (P4) for (a and c) 24 hours or with P4 at (b) 30 ng/ml for various times 
as indicated. Western blot analyses were performed with diverse antibodies as indicated. The expression of snail was inhibited by P4 treatments in 
dose- and time-dependent manners (Figures 1a and b); and the expression of fibronectin, E-cadherin, and occludin was also modulated by P4 in dose 
dependent manners. (d) Morphological changes of MB468 cells treated with/without P4 at 30 ng/ml for 48 hours. Photos (DIC images) were taken by 
using confocal microscopy at 400× magnification. (e) The growth-arrested MB231 cells were treated with different doses of P4 for 24 hours as indi-
cated. Western blot analyses were performed with anti-snail and anti-GAPDH antibodies. Equivalent levels of snail expression were shown after the 
P4 treatment at different doses as indicated. All data were collected and averaged from three individual experiments and the graphs are expressed as 
fold change over basal. * P < 0.05 for difference of protein expression induced by P4 vs. vehicle alone.Zuo et al. Breast Cancer Research 2010, 12:R34
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inhibited by P4. As shown in Additional file 4, the growth
of MB468 cells was inhibited by P4 treatments in a dose-
dependent manner (15 ng/ml - 19%, 30 ng/ml - 29.5%,
and 60 ng/ml - 52.3%, respectively), which is consistent
with the previous report [23]. Interestingly, in the early
passage MB231 cells, another BPBC cell line with obvious
mesenchymal features, the P4 treatment had no effect on
snail expression (Figure 1e) and cell proliferation (data in
Figure 2b).
The nuclear PR has no roles on the P4-repressed EMT in 
MB468 cells
The classical nuclear PR was first considered as a molecu-
lar mediator of the P4-repressed EMT in MB468 cells
even though they are basically negative for nuclear PR
expression in normal culture condition. The cancer pro-
genitor cells, however, may proliferate and express PR in
response to sex hormone treatments [24]. As shown in
Figure 3a, MB468 cells were treated by P4 and estrogen
(E2) and the expression of PR was slightly induced by P4
treatment, but not by E2. To explore whether the increase
of PR expression is involved in the P4-repressed EMT
events, MB468 cells were then co-incubated with P4 plus
RU486 (mifepristone) or R5020 (promegestone), which
are known as a PR-specific blocker or agonist. Surpris-
i n g l y ,  b o t h  P R  m o d u l a t o r s  h a d  n o  e f f e c t s  o n  t h e  P 4
repressed snail expression (Figure 3b) and cell prolifera-
tion (Figure 3c), suggesting that other molecular media-
tors, but not nuclear PR, might be involved in the P4
repressed EMT events.
MPRα plays an essential role in the P4-repressed EMT in 
MB468 cells
Within the past few years, evidence has been obtained for
the involvement of mPRα in the P4's actions in a variety
of cell types [6,7,11,12]. In the present study, the expres-
s i o n  o f  m P R α  i n  M B 4 6 8  c e l l s  w a s  u p - r e g u l a t e d  b y  P 4
treatments in dose-dependent manners (15 ng/ml - 1.97-
fold, 30 ng/ml - 2.75-fold, and 60 ng/ml - 2.92-fold,
respectively; Figure 4a). As a control, there were no
detectable mPRα protein found in MB231 cells (Figure
4b), which is consistent with a previous report [20]. These
data suggest a potential role of mPRα in the P4 signaling
of BPBC cells. To further demonstrate our hypothesis, the
expression of mPRα in MB468 cells was knocked down by
mPRα-specific siRNA. As shown in Additional file 5,
mPRα siRNA specifically inhibited mPRα expression
without affecting α-tubulin expression. After transfection
with 50 nM of mPRα siRNA, the P4's effects on the EMT
marker proteins were significantly inhibited (Figure 4c).
Activation of PI3K/Akt is necessary for P4's action on EMT 
but not on cell proliferation
To further prove the involvement of mPRα in P4's action
on human BPBC cells, the mPRα-expressing plasmid
DNA was introduced into the parent MB231 cells and
then treated by P4 as indicated. There was no reduction
found in the expression of snail as compared with that of
parent MB231 cells (Figure 2a). By comparing the molec-
ular profiles of MB468 and MB231 cells, major differ-
ences were noticed between the two cell lines in
phosphatase and tensin homolog gene (PTEN) expres-
sion and PI3K/Akt activation [15]. PTEN is an essential
inhibitor for the PI3K/Akt pathway [25]. In MB468 cells,
there is no PTEN expression and PI3K/Akt pathway is
constantly activated. On the contrary, in MB231 cells
PTEN is abundantly expressed and PI3K/Akt pathway is
always inactivated. To explore the role of PTEN and
PI3K/Akt pathway in the P4 regulated EMT, the mPRα
stably-expressing MB231 cells were incubated with the
PTEN-specific inhibitor bpV(phen) to transactivate the
PI3K/Akt pathway. As shown in Figure 4d, snail expres-
sion was clearly down-regulated by P4 treatment about
89.8 ± 1.9%. These data strongly suggest that mPRα plays
an important role in the repression of EMT through the
activated PI3K/Akt pathway in BPBCs.
To test whether the female sex hormone controls cell
proliferation of MB468 cells, we incubated the cells with
P4 (30 ng/ml) for 24 hours. As shown in Figure 2a, a 34%
reduction in cell proliferation was observed in the MB468
cells with treatment of P4, as compared with the cells
with treatment of vehicle alone. As expected, P4 had no
Figure 2 Effects of P4 on cell proliferation of (a) MB468, parent 
MB231 and mPRα stably-expressing (b) MB231 cells. The data are 
representative for three individual experiments and the graphs are ex-
pressed as fold change over the basal. The cells treated by E2 (30 pg/
ml for 24 hours) and vehicle alone were used as controls. * P < 0.05 for 
difference of cell proliferation induced by progesterone (P4) vs. vehicle 
alone.Zuo et al. Breast Cancer Research 2010, 12:R34
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effects on cell proliferation of the parental MB231. How-
ever, the treatment of the mPRα stably-expressing MB231
cells with P4 induced a significant reduction of cell prolif-
eration (28.1%; Figure 2b). These data suggest that mPRα
is also involved in regulating cell proliferation of BPBC
cells.
EGFR and PI3K are involved in the P4-repressed EMT in 
MB468 cells
To explore the intermediate pathways that regulate
expression of snail/EMT proteins in the downstream of
P4/mPRα signaling, several pathway specific inhibitors
were tested in the current study. As shown in Figures 5a
and 5b, the EGFR inhibitor (AG1478) and PI3K inhibitor
(wortmannin) significantly blocked the P4-regulated
snail/EMT protein expression in MB468 cells; while the
ERK1/2 inhibitor (PD98059) did not block the P4's effect
on snail/EMT. Additional file 6 showed that P4 induced
phosphorylation of EGFR, Akt, Src, and ERK1/2; and
coordinated pathway inhibitors repressed the P4-induced
phosphorylation, indicating the functionality of these
inhibitors. These results suggest that the signaling cas-
cades of the P4-repressed snail/EMT in MB468 cells are
mainly intermediated through the EGFR and PI3K/Akt
pathways. However, the roles of Src family kinase inhibi-
tor (PP1) in modulating EMT remain unclear as com-
pared with that of other pathway inhibitors. PP1 did not
block the P4's action on expression of snail and fibronec-
tin, but it did block the P4's action on expression of occlu-
din and E-cadherin.
As it has been reported that human BPBC cells often
over express Cav-1, which is a major component of cave-
olae membrane and often negatively regulates the func-
tion of other caveolar-bound signaling molecules
including EGFR [26-29]. To confirm the membrane loca-
tion of mPRα and potential cross relation with other cav-
eolae-bound signaling molecules, the caveolar fraction
proteins were isolated from MB468 cells. As shown in
Figures 6a and b, Cav-1 appeared in the fractions 2 to 4,
suggesting these fractions mainly consist of caveolar
membrane. Importantly, mPRα appeared in the fraction 3
Figure 3 The role of PR in the P4-repressed epithelial-mesenchymal transition and cell proliferation. (a) Growth-arrested MB468 cells were 
treated with progesterone (P4; 30 ng/ml) or E2 (30 pg/ml) for 24 and 48 hours as indicated. (b) Growth-arrested MB468 cells were treated with R5020 
(10 nM) or RU486 (10 nM) for two hours, followed by P4 treatment at 30 ng/ml for 24 hours. Western blot analyses were performed with anti-snail, 
anti-progesterone receptor (PR) and anti-α-tubulin antibodies. (c) MB468 cells were treated with R5020 (10 nM) or RU486 (10 nM) for two hours, fol-
lowed by P4 treatment at 30 ng/ml for 24 hours. Cell proliferation assays were then performed. As shown in the Figures 3a to c, the P4 treatment 
inhibited snail expression and cell proliferation at equivalent levels. The results are representative for three separate experiments.Zuo et al. Breast Cancer Research 2010, 12:R34
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where EGFR was also located, indicating the potential
crosstalk between mPRα and EGFR.
MPRα expression in human benign and malignant breasts
To evaluate expression of mPRα in human breasts, tissue
microarray slides were studied by immunohistochemis-
try. As shown in Table 1, 94 of 105 breast cancer tissues
were stained positive for anti-mPRα. The positive signals
are mainly observed in cytoplasm (Figure 7a) and/or cell
membrane of cancer cells (Figure 7b). There were 14 tri-
ple-negative breast cancers (TNBC) among these breast
cancer tissues. Most of these TNBC (13 of 14) were mod-
erate to strong positive for mPRα stain. In addition,
m P R α  w a s  a l s o  d e t e c t e d  i n  a l l  n o r m a l  a n d / o r  b e n i g n
breast tissues. The ductal and alveolar epithelial cells of
breast were shown to be negative or weak positive while
the myoepithelial cells were shown to be strong positive
for mPRα (Figure 7c).
Discussion
Classically, the actions of P4 on breast cancer cells are
attributed to the binding of nuclear PR and subsequent
activation of the downstream target genes. Lange and col-
leagues proposed that P4 acts as a priming agent in breast
cancer and, in his scenario, breast cells can be directed
toward one path or another by crosstalking between the
P4/PR complex and other signaling pathways [30]. In the
PR-negative MB231 cells, P4 showed no effect on cell
proliferation and invasion. However, after introducing
exogenous PR cDNA into MB231 cells, the PR-expressing
MB231 cells exhibited less proliferative activities after P4
treatment than the parental MB231 cells [31]. With this
PR-expressing cell model, Sumida and colleagues demon-
strated that P4 induced remarkable EMT-like changes in
cell morphology and surface adhesion structures [31]. In
the current study, we showed that P4 treatment in vitro
inhibited EMT relevant proteins in the late passage
MB468 cells. A negative association between P4 and snail
expression was observed (Figure 1b). Consistent with
down-regulation of snail expression, other EMT-relevant
proteins, such as E-cadherin, occludin, and fibronectin,
were subsequently modulated by P4 (Figure 1c); and
these molecular changes were accompanied with cell
Figure 4 The role of mPRα in the P4-repressed EMT of MB468 and MB231 cells. (a) The growth-arrested MB468 cells were treated with diverse 
concentrations of progesterone (P4) for 24 hours. (PC: HEK293 cell lysate as a positive control for membrane progesterone receptor (mPR) α expres-
sion.) (b) MB231 cells and MB468 cells were treated with/without P4 at 30 ng/ml for 24 hours. Western blot analyses were performed with anti-mPRα, 
anti-snail, and anti-α-tubulin antibodies. (c) MB468 cells were transfected with 50 nM of mPRα siRNA and 50 nM of scramble siRNA; and then treated 
with P4 at 30 ng/ml for 24 hours. The Western blot analyses showed similar patterns of snail/epithelial-mesenchymal transition (EMT) protein expres-
sions in the cells transfected with scramble siRNA and equivalent levels of snail/EMT proteins in the cells transfected by mPRα siRNA, indicating the 
roles of specifically knocking down mPRα in MB231 cells. (d) The parent MB231 and mPRα stably-expressing MB231 cells were treated with/without 
bpV(phen) at 1 μM for one hour, followed by P4 treatment at 30 ng/ml. Western blot analyses were performed with anti-snail, anti-mPRα, and anti-α-
tubulin antibodies. The data are representative for three individual experiments.Zuo et al. Breast Cancer Research 2010, 12:R34
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morphological reversion from mesenchymal- to epithe-
lial-like phenotypes (Figure 1d). Our results indicate that
P4 functions as an anti-EMT hormone in MB468 cells in
vitro. It is still unclear how P4 regulates these EMT events
and what the cell mediators of P4 are.
The membrane progestin receptor, mPRα, has recently
been identified as an intermediary factor of the proges-
tin-induced intracellular signaling cascades in the PR-
negative breast cancer cell lines in vitro [6,12]. The
expression of mPRα in human breast cancer tissues, how-
ever, has not been well evaluated. With PCR assay, Dress-
ing and Thomas reported expression of mPRα mRNA in
both normal and malignant breast tissues [7]. Using an in
vitro hormone binding technique and a FITC-conjugated
BSA-progesterone, Pelekanou and colleagues detected
the 'membrane-associate receptor for progesterone' in 57
of 61 breast cancers (94%) [32]. In this report, the protein
expression of mPRα was detected in both human benign
and malignant breasts (Table 1), which is quite consistent
with Pelekanou's result. The receptor was also demon-
strated in all but one triple-negative breast cancer - a type
of cancer that shares many common features with BPBC
[33,34]. Moreover, in the benign breasts, strong positive
stain for mPRα was detected in the basal myoepithelial
cells. Recently we showed that the mammary ducts of
normal mice were positive for both PR and mPRα. The
PR was predominantly seen in the ductal epithelium,
while mPRα was mostly observed in the basal myoepithe-
lial cells [22]. The synergistic roles of mPRα and PR in
normal mammary glands remain to be explored.
The mPRα receptor has been associated with many
physiologic functions in vertebrates. It induces oocyte
maturation, stimulates sperm hypermotility, down-regu-
lates GnRH secretion, modulates T cell functions, and
adjusts human myometrial cell contractility [6,7,11-
13,35]. In agreement with the earlier studies performed in
human myometrial cells and fish oocytes [12,13], we
found that P4 up-regulated the expression of mPRα in
MB468 cells (Figure 4a). Importantly, P4's actions on
expression of snail/EMT-relevant proteins were signifi-
Figure 5 The molecular pathways involved in the P4-repressed EMT of MB468 cells. Growth-arrested MB468 cells were treated with (a) AG1478 
(1 μM) or PP1 (10 μM) and wortmannin (0.1 μM) or (b) PD98059 (50 μM) for one hour, followed by progesterone (P4) treatment at 30 ng/ml for 24 
hours. Western blot analyses were performed with diverse anti-snail and/or epithelial-mesenchymal transition (EMT) relevant antibodies as indicated. 
The data are representative for three individual experiments.Zuo et al. Breast Cancer Research 2010, 12:R34
http://breast-cancer-research.com/content/12/3/R34
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cantly blocked by the mPRα specific siRNA (Figure 4c).
In contrast, P4 treatment alone had no effect on snail
expression in the parent MB231 cells, in which mPRα
protein is undetectable by western blot assay (Figure 4b).
We thought that the exogenous mPRα cDNA stable
transfection would cause the cell EMT responding to the
P4 treatment. Unexpectedly, the expression of snail/EMT
relevant markers remained unchanged after P4 treat-
ments, indicating other factors in the P4/mPRα signaling
pathway were still blocked.
The mesenchymal phenotype of MB231 cells under
normoxic culture conditions has been associated with
high levels of urokinase-type plasminogen activator
(uPA) and uPA receptor (uPAR) expression and silencing
uPA expression decreased expression of vimentin and
snail and induced epithelial-like transition in the cells
[16]. In the current study, we showed that the P4
repressed EMT in MB231 cells is correlated to the
mutant pten and activation of PI3K/Akt signaling path-
way. PTEN is a major inhibitor of the PI3K/Akt signaling
pathway. Loss of PTEN protein expression occurs com-
monly in breast cancer, which has been associated with
loss of ER [36] and resistance to cancer therapies [37].
The PTEN-deficient cell lines displayed greater sensitiv-
ity to the growth inhibitory effects of the PI3K inhibitor,
LY294002, as compared with the PTEN-positive cell lines
[38]. Recently major differences have been reported in
the status of PI3K/Akt pathway and function of PTEN
between MB468 and MB231 cells [15,39]. It was assumed
that the activation of PI3K/Akt pathway, resulting from a
dysfunctional PTEN, is essential for the P4-repressed
EMT. In further study, we demonstrated that the expres-
sion of snail/EMT-relevant proteins in the mPRα express-
ing MB231 cells was significantly modulated after
incubating the cells with P4 plus PTEN inhibitor -
bpV(phen) (Figure 4d). However, activation of PI3K/Akt
seems not to be essential for the P4-repressed cell prolif-
eration because the growth reduction of the mPRα-
expressing MB231 cells could be induced by P4 treatment
alone. It is assumed that the P4 inhibited cell proliferation
may go through other pathways, such as the secondary
messenger pathway through activation of pertussis toxin-
sensitive inhibitory G proteins and MAPK/Erk1/2
[12,20].
When exploring the intermediate pathways that regu-
late snail/EMT in P4 signaling, we showed that P4's
Figure 6 Co-localization of mPRα and EGFR in caveolar mem-
brane of MB468 cells. Caveolar (Cav) fractions were isolated and im-
munoblotted for detecting Cav-1, membrane progesterone receptor 
(mPR) α, and epidermal growth factor receptor (EGFR) after the MB468 
cells were treated (a) without and (b) with progesterone (P4) at 30 ng/
ml for 24 hours. The Figures 6a and b show that Cav-1, mPRα, and EGFR 
are co-localized in the caveolar fraction #3 component regardless of P4 
treatments. The results are representative for two separate experi-
ments. PC, mPRα positive cells (HEK293).
Table 1: Positivity of mPRα expression in human breast 
cancers
mPRα reactivity TNBC Non TNBC Total
Positive (%) 13 (92.9) 81 (89) 94(89.5)
Negative 1 10 11
Total 14 91 105
No significant difference was found between the positive rates of 
mPRα (TNBC vs. non TNBC groups, P = 0.312, Fisher's exact test). 
MPRα, membrane progesterone receptor α; TNBC, triple-
negative cancers.
Figure 7 Expression of mPRα in human breast cancer tissues. (a 
and b) The low to intermediate intensities of membrane progesterone 
receptor (mPR) α stains in the cytoplasm of most human breast cancer 
cells. Apparent cytoplasm-membrane stains were observed in some of 
the cancer cells (black arrows). (c) The immunostain of mPRα in normal 
human breast. EP,ductal epithelium; MEP, myoepithelium.Zuo et al. Breast Cancer Research 2010, 12:R34
http://breast-cancer-research.com/content/12/3/R34
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actions on EMT were significantly blocked in the late
passage MB468 cells by AG1478 (an EGFR inhibitor) and
wortmannin (PI3K inhibitor), suggesting EGFR and
PI3K/Akt pathways are involved in the P4 repressed EMT
events. Studies have shown that along with other signal-
ing molecules such as PDGFR, Ha-ras, and c-Src, both
EGFR and PI3K are distributed in the caveolar vesicles in
which Cav-1 serves as a main structure component [40].
Cav-1 usually functions as a negative regulator of other
caveolar-bound signaling molecules [26-29]. Existing
data has shown that BPBC is associated with high expres-
sion of Cav-1 [41,42] and EMT of cancer cells is depen-
dent upon the presence of Cav-1 [40]. Okamoto and
colleagues showed that long-term EGF treatment
reduced expression of Cav-1 in cancer cells; and subse-
quently up-regulated snail and down-regulated E-cad-
herin expression [40]. Lu and colleagues demonstrated
that EGF treatment of human tumor cells that over
express EGFR caused a dramatic alteration in cell-cell
contacts and internalization of E-cadherin [43]. It was
assumed that upon binding to EGF, EGFR forms homodi-
mers or heterodimers which result in the activation of
their intrinsic kinases and autophosphorylation of spe-
cific tyrosine residues within their cytoplasmic domains
[44]. The activated EGFR may recruit other molecular
signaling complexes such as PI3K, via several potential
paths. For example, EGFR may bind to and recruit PI3K
directly because the canonical binding sites for the regu-
latory subunit of PI3K are not found on EGFR [45]; it may
also employ the docking protein Gab1 to recruit PI3K
[46]. In addition, the EGFR adapter (Shc) may recruit
PI3K by assembly of a Shc-Grb2-Gab2-PI3K complex
[47]. The role of PI3K/Akt pathway in cancer EMT has
been well documented in various human malignancies
[48-50]. The proposed mPRα dependent molecular path-
ways that inhibit EMT of BPBC are schematically illus-
trated in Figure 8.
The essential roles of c-Src pathway in the P4/PR sig-
naling pathways have been demonstrated in human
breast cancer cells that is T47 D cells. The cell anchorage-
independent growth was stimulated by progestin and
b l oc k ed  b y  i n h i b i t i o n  o f  E r k 1 / 2 ,  c - S r c,  E G F R,  o r  RN A
interference of Wnt-1 [51]. Recently Lester and col-
leagues reported that when MB468 breast cancer cells
were cultured in a hypoxia condition expression of uPAR
was increased, cell-cell junctions were disrupted, vimen-
tin expression was increased, and E-cadherin was lost
from cell surfaces, indicating enhancement of EMT
[16,52]. Lester and colleagues proposed a model in which
Src family kinases may concert with other cell signaling
factors, including PI3K and ERK1/2 and play an essential
role in the regulation of uPA and uPAR and EMT [16]. In
this report, we found that in the late passage MB468 cells,
the Src family kinases inhibitor (PP1) did not block the
P4's action on snail and fibronectin (one of the mesenchy-
mal phenotypes), but it blocked the P4's action on expres-
sion of occludin and E-cadherin (epithelial phenotypes).
The roles of Src family kinases on the P4-repressed EMT
remain to be explored.
Conclusions
In summary, using two human BPBC cell lines as models,
we identified a PR-independent pathway that involves the
signaling cascade of EMT through a caveolae-bound sig-
naling complex namely mPRα, Cav-1, EGFR, and PI3K/
Akt. It is assumed that mPRα receptor is the key modula-
tor of EMT located on the caveolar membrane of BPBC
cells. Through the receptor-mediated mechanisms, P4
directly inactivates the PI3K-snail-EMT pathway or inter-
acts with Cav-1 and modulates the activities of the EGFR
pathway, which then cross inhibit PI3K pathway, and
eventually suppresses the cell EMT. The proposed path-
way is attractive for further understanding the molecular
mechanisms of EMT and for developing novel therapeu-
tic strategies against BPBC.
Figure 8 Schematic illustration of molecular pathway initiated by 
P4 signaling in BPBC cells. MB468 cells usually maintain the activities 
of PI3K/Akt at high levels because these cells contain a mutant pten 
gene and over expressed epidermal growth factor receptor (EGFR). Ac-
tivation of PI3K/Akt pathway is a vital signal for cell survival and epithe-
lial to mesenchymal transition (EMT). It is assumed that the binding of 
progesterone (P4) to membrane progesterone receptor (mPR) α in the 
caveolar membrane of the cells inhibits EMT-relevant events either di-
rectly through Caveolar (Cav) 1 activation or through a cross interac-
tion with EGFR and trans-activation of Cav-1 which subsequently 
inactivate PI3K/Akt pathway. Inactivation of PI3K/Akt pathway subse-
quently inhibits the nuclear translocation of snail and then modulates 
expression of other EMT-relevant proteins.Zuo et al. Breast Cancer Research 2010, 12:R34
http://breast-cancer-research.com/content/12/3/R34
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